Rigel Pharmaceuticals, Inc. provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2025.
The company anticipates full-year total revenue of approximately $275 to $290 million for 2026, with positive net income expected for the year.
Commercial sales for key products, including TAVALISSE, GAVRETO, and REZLIDHIA, showed significant growth in the fourth quarter of 2025.
Strong Financial Performance
Preliminary fourth quarter 2025 total revenue was approximately $69.8 million, with net product sales of $65.4 million and contract revenues of $4.4 million.
Commercial Success
Significant growth in net product sales for key products such as TAVALISSE, GAVRETO, and REZLIDHIA, contributing to the overall positive financial outlook for 2026.
Clinical Development Progress
Progress in the Phase 1b study of R289 in patients with lower-risk MDS, with promising data indicating potential clinical advancements in the future.
- Rigel Pharmaceuticals achieved strong financial results in the fourth quarter of 2025, driven by robust commercial performance and growth in key product sales.
- The company's strategic focus on commercial execution and clinical development is reflected in the positive outlook for 2026 and beyond, emphasizing potential for sustained growth and profitability.
Rigel Pharmaceuticals' solid financial performance in 2025, coupled with ongoing clinical advancements, positions the company for continued success in 2026 and beyond.